Relmada Therapeutics Inc

NASDAQ:RLMD   3:59:57 PM EDT
18.86
-1.00 (-5.04%)
Products

Relmada Therapeutics Announces Publication Of REL-1017 Phase 2 Study Results In The American Journal Of Psychiatry

Published: 12/22/2021 14:12 GMT
Relmada Therapeutics Inc (RLMD) - Relmada Therapeutics Announces Publication of Rel-1017 Phase 2 Study Results in the American Journal of Psychiatry.
Relmada Therapeutics Inc - Primary Endpoint Results Included Rapid, Significant, and Sustained Efficacy Versus.
Placebo.
Relmada Therapeutics - Safety Analysis Showed Adverse Event Profile Comparable to Placebo for Rel-1017 Phase 2 Study.